Effects of insulin and sitagliptin on early cardiac dysfunction in diabetic rats

Life Sci. 2022 Jun 15:299:120542. doi: 10.1016/j.lfs.2022.120542. Epub 2022 Apr 6.

Abstract

Aims: Cardiac affection is common in diabetic patients. Although insulin exerts a cardioprotective role, it may not be enough to totally prevent this affection. The current study aimed to compare the cardioprotective effect of insulin alone or combined with sitagliptin in a rat model of type 1 diabetes mellitus.

Materials and methods: Diabetes was induced by a single intraperitoneal injection of streptozotocin (STZ; 60 mg/kg). Diabetic rats were treated with insulin (3 IU), insulin (6 IU), or insulin (3 IU) + sitagliptin (10 mg/kg) for 42 days.

Key findings: Diabetic rats exhibited significant systolic and diastolic cardiac affection with significant elevation of tumor necrosis factor α (TNF-α), interleukin 6 (IL-6) and brain natriuretic peptide (BNP) levels. Treatment with insulin prevented the deterioration of diabetes-induced cardiac condition, an effect that was significantly potentiated by the combined use of sitagliptin.

Significance: The combined use of sitagliptin and insulin significantly improved the cardioprotective effect of insulin and prevented the early cardiac dysfunction in STZ diabetic rats.

Keywords: Cardiac; Diabetes; Insulin; STZ; Sitagliptin; TNF-α.

MeSH terms

  • Animals
  • Diabetes Mellitus, Experimental* / complications
  • Diabetes Mellitus, Experimental* / drug therapy
  • Diabetes Mellitus, Experimental* / pathology
  • Heart Diseases*
  • Humans
  • Insulin
  • Rats
  • Sitagliptin Phosphate / pharmacology
  • Streptozocin

Substances

  • Insulin
  • Streptozocin
  • Sitagliptin Phosphate